| Ian Reilly, MD | |
|
9888 Genesee Ave, La Jolla, CA 92037-1205 | |
| (858) 354-6049 | |
| Not Available |
| Full Name | Ian Reilly |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 24 Years |
| Location | 9888 Genesee Ave, La Jolla, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073581914 | NPI | - | NPPES |
| 00A764230 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A76423 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Scripps Memorial Hospital La Jolla | La jolla, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| La Jolla Emergency Specialists | 1153552039 | 15 |
| La Jolla Observation Medicine | 2365727492 | 23 |
News Archive
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1
People who take drugs that suppress the immune system are less likely to develop Parkinson's disease, according to a study from Washington University School of Medicine in St. Louis.
In recent years, scientists have studied the possibility of using engineered human adenoviruses as vaccines against diseases such as HIV, tuberculosis, and malaria. In this approach, adenoviruses, which commonly cause respiratory-tract infections, are rendered relatively harmless before they are used as vectors to deliver genes from pathogens, which in turn stimulate the body to generate a protective immune response.
Boston AIDS Africa, a Boston-based initiative to respond to the AIDS pandemic in Africa by providing vital supplies to care for those suffering with HIV/AIDS in Africa, announced today that it has partnered with Massachusetts Institute of Technology (MIT) in Cambridge, who will host a community-wide Caregiver Kit Build Event on April 3, 2010 at the MIT Johnson Ice Rink.
They wriggle and turn and explore new territory until they find something edible, and then they stay the course until the food disappears.
› Verified 7 days ago
| Entity Name | La Jolla Emergency Specialists |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710315353 PECOS PAC ID: 1153552039 Enrollment ID: O20140317001669 |
News Archive
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1
People who take drugs that suppress the immune system are less likely to develop Parkinson's disease, according to a study from Washington University School of Medicine in St. Louis.
In recent years, scientists have studied the possibility of using engineered human adenoviruses as vaccines against diseases such as HIV, tuberculosis, and malaria. In this approach, adenoviruses, which commonly cause respiratory-tract infections, are rendered relatively harmless before they are used as vectors to deliver genes from pathogens, which in turn stimulate the body to generate a protective immune response.
Boston AIDS Africa, a Boston-based initiative to respond to the AIDS pandemic in Africa by providing vital supplies to care for those suffering with HIV/AIDS in Africa, announced today that it has partnered with Massachusetts Institute of Technology (MIT) in Cambridge, who will host a community-wide Caregiver Kit Build Event on April 3, 2010 at the MIT Johnson Ice Rink.
They wriggle and turn and explore new territory until they find something edible, and then they stay the course until the food disappears.
› Verified 7 days ago
| Entity Name | La Jolla Observation Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780122986 PECOS PAC ID: 2365727492 Enrollment ID: O20170331001702 |
News Archive
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1
People who take drugs that suppress the immune system are less likely to develop Parkinson's disease, according to a study from Washington University School of Medicine in St. Louis.
In recent years, scientists have studied the possibility of using engineered human adenoviruses as vaccines against diseases such as HIV, tuberculosis, and malaria. In this approach, adenoviruses, which commonly cause respiratory-tract infections, are rendered relatively harmless before they are used as vectors to deliver genes from pathogens, which in turn stimulate the body to generate a protective immune response.
Boston AIDS Africa, a Boston-based initiative to respond to the AIDS pandemic in Africa by providing vital supplies to care for those suffering with HIV/AIDS in Africa, announced today that it has partnered with Massachusetts Institute of Technology (MIT) in Cambridge, who will host a community-wide Caregiver Kit Build Event on April 3, 2010 at the MIT Johnson Ice Rink.
They wriggle and turn and explore new territory until they find something edible, and then they stay the course until the food disappears.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ian Reilly, MD 9888 Genesee Ave, La Jolla, CA 92037-1205 Ph: (858) 354-6049 | Ian Reilly, MD 9888 Genesee Ave, La Jolla, CA 92037-1205 Ph: (858) 354-6049 |
News Archive
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1
People who take drugs that suppress the immune system are less likely to develop Parkinson's disease, according to a study from Washington University School of Medicine in St. Louis.
In recent years, scientists have studied the possibility of using engineered human adenoviruses as vaccines against diseases such as HIV, tuberculosis, and malaria. In this approach, adenoviruses, which commonly cause respiratory-tract infections, are rendered relatively harmless before they are used as vectors to deliver genes from pathogens, which in turn stimulate the body to generate a protective immune response.
Boston AIDS Africa, a Boston-based initiative to respond to the AIDS pandemic in Africa by providing vital supplies to care for those suffering with HIV/AIDS in Africa, announced today that it has partnered with Massachusetts Institute of Technology (MIT) in Cambridge, who will host a community-wide Caregiver Kit Build Event on April 3, 2010 at the MIT Johnson Ice Rink.
They wriggle and turn and explore new territory until they find something edible, and then they stay the course until the food disappears.
› Verified 7 days ago
Mrs. Susan Elizabeth Mckim, PA-C Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 10666 N Torrey Pines Rd, La Jolla, CA 92037 Phone: 858-554-8646 Fax: 858-554-6271 | |
Dr. Monte Tim Mellon, M.D. M.B.A. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 9888 Genesee Ave, La Jolla, CA 92037 Phone: 858-626-6150 Fax: 858-626-7117 | |
Richard M Obler, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 354 Ricardo Pl, La Jolla, CA 92037 Phone: 858-922-1073 | |
Ian R Grover, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 9300 Campus Point Drive, La Jolla, CA 92037 Phone: 858-657-7000 | |
George R Baehr, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 10710 N Torrey Pines Rd, La Jolla, CA 92037 Phone: 858-554-8638 | |
Sean X Neath, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 9300 Campus Point Dr, La Jolla, CA 92037 Phone: 858-657-7000 |